|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PDCD5 may be a novel tumor suppressor gene, and may be potentially used for cancer treatment in the future.
|
29403562 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PDCD5 levels, histological grade, and tumor stage were independent predictors of overall survival.
|
27255549 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Importantly, Pdcd5 expression induced tumor cell apoptosis, and the apoptotic proteins caspase-3 and -9 were activated.
|
25109624 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The functional importance of PDCD5 as a regulating agent in cell apoptosis suggests that it may play a key role in tumour pathogenesis and development.
|
24265335 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PDCD5 expression was significantly associated with HBV infection, tumor number, lymph node metastasis and the survival time of the patients with HCC.
|
23807738 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, decreased PDCD5 expression was significantly associated with clinicopathological characteristics including tumor size and mitosis.
|
22965478 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Accordingly, the survival rate of these mice was significantly higher than that of mice bearing tumors that did not express PDCD5.
|
22560879 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Importantly, expression of PDCD5 also markedly inhibited tumor cell proliferation and colony formation in the presence of low doses of cisplatin.
|
22688731 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In in vivo study, the transfection of PDCD5 increased the efficacy of cisplatin-induced inhibition of tumor growth in nude mice.
|
20869960 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low expression of PDCD5 protein was 61.8% (21/34) in chondrosarcomas, as compared 12.5% (1/8) in normal bones, as well as compared 23.5% (4/17) in benign cartilage tumors.
|
20872801 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
At a dose of 1 x 10(9) plaque-forming units, SG611-PDCD5 alone could completely inhibit the tumor growth and more effective than replication-defective Ad-PDCD5.
|
19551515 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results suggest that the rs1862214 polymorphism in PDCD5 is predictive for lung cancer risk and prognosis, and that PDCD5 may represent a novel tumor suppressor gene influencing lung cancer.
|
16549820 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we have systematically employed the approaches of RT-PCR, Real- time PCR, Immunohistochemistry (IHC), Immunofluorescence staining (IFS) and Western blot to determine the PDCD5 expression in GC cells and primary tumors, at mRNA and protein level, respectively.
|
16547588 |
2006 |